Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)

Authors: Christopher M. O’Connor, Wendy A. Gattis, Barry F. Uretsky, Kirkwood F. Adams, Steven E. McNulty, Steven H. Grossman, William J. McKenna, Faı̈ez Zannad, Karl Swedberg, Mihai Gheorghiade, Robert M. Califf - American Heart Journal 1999 cited by 518